$5bn Galapagos Deal Won’t Be Last For Gilead, Says O’Day

 
• By Eleanor Malone
  
Generate a summary of this article
Listen to this article
Beta

Handing over $5bn to Galapagos for access to several shots on the inflammation/fibrosis goal, Gilead Sciences CEO Daniel O’Day is still on the prowl for more.

Foundations
Gilead is building R&D foundations for future growth

Gilead Sciences Inc. has agreed a new deal worth $5.05bn with existing partner Galapagos NV which sees the US firm increasing its stake in the Belgian biotech, although it won’t go above 30% and is still on the lookout for additional deals to swell its pipeline. Gilead will pay $3.95bn in cash upfront, and $1.1bn for an equity investment, plus additional milestones and royalties.

The deal gives Gilead access to six clinical compounds, including GLPG1690, in Phase III for idiopathic pulmonary fibrosis (IPF), GLPG1972...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.